Amryt Pharma (AMYT) Share Price, News & Analysis

Company Overview

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: 143 to 155
• 50-Day Range: 143 to 143
• 52-Week Range: 135 to 230
• Volume: 90,726 shs
• Average Volume: 469,552 shs
• Market Capitalization: £457.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMYT Stock Analysis - Frequently Asked Questions

How have AMYT shares performed this year?

Amryt Pharma's stock was trading at GBX 143 at the start of the year. Since then, AMYT stock has increased by 0.0% and is now trading at GBX 143.
View the best growth stocks for 2024 here.

How do I buy shares of Amryt Pharma?

Shares of AMYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amryt Pharma investors own include The Parkmead Group (PMG), Providence Resources (PVR), Ryanair (RYA), AIB Group (AIBG), Atalaya Mining (ATYM), Bank of Ireland Group (BIRG) and C&C Group (CCR).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:AMYT
• Previous Symbol: LON:FAST
• CUSIP: N/A
• CIK: N/A
• Web: www.amrytpharma.com
• Phone: +44-20-34155730
• Fax: N/A
• Employees: 290
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 66.05
• Current Ratio: 1.80
• Quick Ratio: 1.14

Sales & Book Value

• Annual Sales: £210.24 million
• Price / Sales: 2.17
• Cash Flow: GBX 38.90 per share
• Price / Cash Flow: 3.68
• Book Value: GBX 96.60 per share
• Price / Book: 1.48

Miscellaneous

• Outstanding Shares: 319,657,000
• Free Float: N/A
• Market Cap: £457.11 million
• Optionable: Not Optionable
• Beta: N/A